https://doi.org/10.55788/c3fee35c
Prof. Lisa Mielniczuk (University of Ottawa, Canada), who presented the results, said that the role of revascularisation in patients with HF due to underlying ischaemic heart disease remains subject to debate [1]. The overall objective of the pragmatic AIMY-HF (NCT01288560) was to determine the impact of advanced imaging modalities with PET or CMR compared with SPECT on a CV composite of cardiac death, myocardial infarction (MI), resuscitated cardiac arrest, and cardiac hospitalisation.
Enrolled participants had HF with reduced ejection fraction (HFrEF) and suspected or known coronary artery disease. Participants were first evaluated for either the burden of their ischaemia or existing evidence of myocardial viability. Then 271 participants from 15 sites were randomised to advanced (CMR or PET) or standard (SPECT) imaging modalities, depending on availability at their site. An additional registry arm was created (n=1,110) to enhance the study's power and to allow patients to be included who could not be randomised, either due to contraindication or clinician preference. The primary outcome was time to CV composite. Of the 1,381 participants, 672 had ischaemia as the primary clinical question and 709 myocardial viability. The advanced imaging group had 1,069 patients, and the SPECT group included 312. The median follow-up was 24.1 months.
In the total study population, the cumulative incidence of the primary composite outcome occurred in 31% and 35% of patients undergoing CMR or PET and SPECT, respectively. The difference was not statistically significant (HR 0.95; 95% CI 0.71–1.25; P=0.696). In the ischaemia cohort, the difference did not reach statistical significance either (HR 0.86; 95% CI 0.61–1.21; P=0.388). Prof. Mielniczuk added that there was a marginally significant reduction in cardiac death in the PET arm of the ischaemia cohort versus the SPECT arm (HR 0.61; 95% CI 0.38–1.00; P=0.05).
Turning to the randomised patients, no difference was observed in the primary composite outcome either, occurring in 28% in the CMT or PET group versus 30% in the SPECT group (HR 0.88; 95% CI 0.55–1.43; P=0.662). There was also no significant difference in cardiac death.
In the total population, patients in the advanced imaging group were more likely to undergo revascularisation (P<0.0001), with 61% undergoing revascularisation via CABG. Although not reaching statistical significance, a trend was observed toward benefit for patients who underwent revascularisation after CMT or PET imaging.
Prof. Mielniczuk concluded that the imaging strategy was not associated with a difference in CV outcomes in patients with HF. Whether an advanced imaging modality is associated with a reduction in CV death compared with SPECT would need to be evaluated in future studies.
- Mielniczuk L. Ischemia and viability imaging in heart failure: The alternative imaging modalities in ischemic heart failure trial. Session 403-12, ACC Scientific Session 2023, 4–6 March, New Orleans, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Benefits of MitraClip sustained to 5 years in COAPT trial Next Article
No need to restrict vigorous exercise in selected HCM patients? »
« Benefits of MitraClip sustained to 5 years in COAPT trial Next Article
No need to restrict vigorous exercise in selected HCM patients? »
Table of Contents: ACC 2023
Featured articles
Pulmonary Arterial Hypertension
Sotatercept improves exercise capacity in patients with PAH
Fixed-dose macitentan plus tadalafil superior to either agent alone in PAH
Coronary Revascularisation
Immediate complete revascularisation non-inferior to staged complete revascularisation
RENOVATE-COMPLEX-PCI results support intravascular-guided PCI for complex lesions
Heart Failure and Cardiomyopathy
No need to restrict vigorous exercise in selected HCM patients?
No difference in CV outcomes between PET or CMR and SPECT
Interventional and Structural Cardiology
Benefits of MitraClip sustained to 5 years in COAPT trial
Transcatheter repair for patients with tricuspid regurgitation
Minimally invasive versus conventional sternotomy for mitral valve repair
Durable benefits of TAVR versus surgical aortic valve replacement in aortic stenosis patients
PCI not better than GDMT in severe ischaemic cardiomyopathy
Prevention
Anticoagulation in non-critically ill hospitalised COVID patients
Statins associated with reduced heart dysfunction from anthracyclines
Multifaceted strategy improves prescription of therapies for diabetes and ASCVD
Dyslipidaemia
Bempedoic acid benefits statin-intolerant patients at high cardiovascular risk
Evolocumab improves coronary plaque morphology in stable CAD
Inflammation stronger predictor of MACE than cholesterol levels
Oral PCSK9 inhibitor significantly lowers LDL-C
Miscellaneous
Baxdrostat in patients with uncontrolled hypertension
Hormone therapy for gender dysphoria associated with increased CV risk
Pulsed-field ablation appears safe and effective for atrial fibrillation
Key correlates of incident dementia identified in the MESA study
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy